Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3468332 | 0.93 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2L3MBTL1RBP4 | |
| SCHEMBL19384148 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL524534 | 0.85 | HDAC1 (0.39) | KDM4EALDH1A1SMN1; SMN2L3MBTL1RBP4 | |
| SCHEMBL19384155 | 0.82 | HTR1D (0.56) | SMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL3468335 | 0.81 | PDK2 (0.40) | KDM4EALDH1A1SMN1; SMN2RBP4SLC6A9 | |
| SCHEMBL524535 | 0.80 | MEN1 (0.39) | KDM4EALDH1A1L3MBTL1LMNAHRH1 | |
| Trifluoroacetic Acid SCHEMBL523116 | 0.80 | RBP4 (0.39) | KDM4EALDH1A1LMNARBP4HRH1 | |
| Trifluoroacetic Acid SCHEMBL523117 | 0.75 | LPAR1 (0.37) | L3MBTL1 | |
| SCHEMBL16524239 | 0.75 | ALDH1A1 (0.41) | KDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL25388128 | 0.75 | HTR7 (0.66) | KDM4EALDH1A1SMN1; SMN2L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433237-A1 | CRYSTALLINE FORM | Astrazeneca AB (SE) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162304-A1 | CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA UK LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8969350-B2 | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | ASTRAZENECA AB (SE) | 2015-03-03 | — | — | US | disclosed |
| WO-2010071583-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | NR3C2, GRK4, PTGER2 | KDM4E 2414/4885ALDH1A1 1934/4885SMN1; SMN2 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.